Patterns of immune-related adverse events and treatment responses in adolescents and young adults with melanoma during initial and rechallenge immune checkpoint inhibitor therapy.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) are increasingly used in adolescents and young adults (AYAs) with cancer; however, data on treatment response, the frequency and pattern of immune-related adverse events (irAEs), and the feasibility of ICI rechallenge after irAEs are limited.

Methods

This retrospective study included 136 AYAs (80 males and 56 females) who received ICI therapy for melanoma at our institution from 2013 to 2023. We documented the initial ICI treatment and ICI rechallenge, along with associated irAEs and treatment responses. Kaplan-Meier plots were used to analyze overall survival (OS) and progression-free survival.

Results

At ICI initiation, the median age was 33 (range, 15-39) years, and most patients had stage III or IV disease (93%) and <

SUBMITTER: He J 

PROVIDER: S-EPMC12699720 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature